<DOC>
	<DOCNO>NCT02432612</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) single oromucosal dose Sativex subject advance cancer currently background Step III opioid therapy .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetic ( PK ) Properties Sativex® Patients With Advanced Cancer</brief_title>
	<detailed_description>This open-label , multiple-centre , single dose clinical trial ass PK single oromucosal dose Sativex subject advance cancer currently background Step III opioid therapy . A minimum 25 subject ≥18 year advance cancer need assessment primary objective trial . The Screening Visit ( Visit 1 ) perform within -10 -2 day prior dose . For Screening Visit , subject attend outpatient basis . Subjects check clinical research facility Day −1 confine clinical research facility Inpatient/Treatment Period ( Day −1 Day 3 ) ( Visit 2 ) . Subjects administer single oromucosal dose Sativex Day 1 ( time [ ] =0 ) . Fourteen PK blood sample take Day 1 Day 3 Visit 2 : one predose sample 13 postdose sample follow time point dose : 0.25 , 0.5 , 0.75 , 1 , 1.5 , 2 , 4 , 6 , 8 , 12 , 24 , 36 , 48 hour postdose . Subjects discharge clinical research facility 48-hour PK blood sample take final safety assessment complete . Subjects discontinue trial prior completion PK blood draw undergo safety evaluation schedule Day 3 . The Safety Follow-up Call ( Visit 3 ) make 7 ( +2 ) day dose Day 1 . Subjects new adverse event ( AEs ) clinical laboratory abnormality ask return safety follow-up . The expected duration trial participation ( include Screening Visit , Inpatient/Treatment Period , Safety Follow-up Call ) individual subject maximum 19 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>For inclusion trial subject must fulfil ALL follow criterion : The subject age ≥18 year . The subject advance cancer know curative therapy . The subject clinical diagnosis cancer relate pain , currently take Step III opioid therapy willing continue current dosing regimen throughout Inpatient/Treatment Period trial . The subject willing able give write informed consent . The subject willing able comply trial requirement . The subject may enter trial ANY follow apply : The subject receive intrathecal opioids via pump mechanism . The subject currently use use cannabis cannabinoid base medication within 30 day trial entry unwilling abstain duration trial . The subject know suspected history substance abuse/dependence disorder ( include opiate abuse/dependence prior diagnosis cancer ) ; current heavy alcohol consumption ( 60 gram pure alcohol per day men , 40 gram pure alcohol per day woman ) unwilling abstain alcohol 24 hour prior trial visit ; current use illicit drug current non prescribe use prescription drug . The subject history epilepsy evidence one seizure last 12 month . The subject know suspected history family history schizophrenia , psychotic illness , history severe personality disorder severe significant psychiatric disorder depression associate underlying condition . The subject know suspected hypersensitivity cannabinoids excipients IMP . The subject significant cardiac disease , cardiac disorder opinion investigator would put subject risk clinically relevant arrhythmia myocardial infarction , secondary tertiary atrioventricular block , evidence clinically significant cardiac disease ECG Screening Visit . The subject significantly impair renal function evidence creatinine clearance ( base measure serum creatinine level ) low 40 mL/min Visit 1 . The subject significantly impair hepatic function Visit 1 ( alanine aminotransferase [ ALT ] &gt; 5 upper limit normal ( ULN ) total bilirubin [ TBL ] &gt; 2 ULN ) . If ALT aspartate aminotransferase [ AST ] &gt; 3 ULN TBL &gt; 2 ULN [ international normalize ratio [ INR ] &gt; 1.5 ] ) subject must enter trial . The subject female childbearing potential , male patient whose partner childbearing potential , unwilling ensure and/or partner use highly effective method contraception , include female sterilization ( ie , documented bilateral tubal ligation ) , male sterilization , establish use hormonal method contraception ( oral , implanted transdermal ) , intrauterine device intrauterine system , true abstinence . Female subject pregnant , lactate plan pregnancy course trial 3 month thereafter . The subject receive non approve IMP within 30 day 5 time halflife IMP ( whichever great ) prior Screening Visit . The subject significant disease disorder , opinion investigator , may either put patient risk participation trial , may influence result trial , patient 's ability participate trial . The subject previously enrol current trial Sativex clinical trial cancer pain . The subject unwilling abstain consumption grapefruit product week prior throughout Inpatient/Treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>